de Havenon, Adam http://orcid.org/0000-0001-8178-8597
Ney, John P.
Callaghan, Brian
Yaghi, Shadi
Majersik, Jennifer J.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (K23NS105924)
Article History
Received: 16 June 2020
Revised: 11 July 2020
Accepted: 14 July 2020
First Online: 20 July 2020
Compliance with ethical standards
:
: Dr. de Havenon has received investigator initiated funding from AMAG and Regeneron pharmaceuticals. Dr. Callaghan consults for a PCORI grant, DynaMed, and performs medical legal consultations including consultations for the Vaccine Injury Compensation Program. Dr. Majersik reports NIH/NINDS funding U24NS107228, funding for Associate Editor at <i>Stroke</i>, consulting fees for Foldax scientific advisory board, and is an Editorial Board member of <i>Neurology</i>. The remaining authors report no potential conflicts of interest.
: IRB approval was not required for this retrospective analysis of deidentified data per the University of Utah Institutional Review Board Guidelines.
Free to read: This content has been made available to all.